• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: Neoadjuvant Chemotherapy Combined with Immunotherapy is a Promising Strategy for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.

作者信息

Sun Xiong, Lyu Jianbo, Yin Yuping, Tao Kaixiong

机构信息

Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.

出版信息

Ann Surg Oncol. 2024 Nov;31(12):8179-8180. doi: 10.1245/s10434-024-16152-5. Epub 2024 Aug 30.

DOI:10.1245/s10434-024-16152-5
PMID:39212861
Abstract
摘要

相似文献

1
ASO Author Reflections: Neoadjuvant Chemotherapy Combined with Immunotherapy is a Promising Strategy for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.ASO作者反思：新辅助化疗联合免疫疗法是局部晚期胃癌和胃食管交界腺癌的一种有前景的策略。
Ann Surg Oncol. 2024 Nov;31(12):8179-8180. doi: 10.1245/s10434-024-16152-5. Epub 2024 Aug 30.
2
Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial.新辅助化疗和免疫治疗局部晚期胃和胃食管结合部腺癌的两年结果和生物标志物分析：来自 II 期武汉 UHGI001 试验的结果
Ann Surg Oncol. 2024 Nov;31(12):8157-8169. doi: 10.1245/s10434-024-16041-x. Epub 2024 Aug 17.
3
Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastro-oesophageal junction adenocarcinoma: study protocol for a single-arm, phase II clinical trial.化疗联合卡度尼利单抗（AK104）作为局部晚期胃/胃食管交界腺癌的新辅助治疗：一项单臂、II期临床试验的研究方案
BMJ Open. 2024 Dec 4;14(12):e081529. doi: 10.1136/bmjopen-2023-081529.
4
Chemotherapy for Esophageal Adenocarcinoma.食管腺癌的化疗
Methods Mol Biol. 2018;1756:19-34. doi: 10.1007/978-1-4939-7734-5_3.
5
SOX combined with tislelizumab and low-dose radiation therapy for the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase Ib/II clinical trial.SOX 联合替雷利珠单抗和低剂量放疗用于局部晚期胃/胃食管结合部腺癌的新辅助治疗：一项前瞻性、多中心、单臂、Ib/II 期临床试验的研究方案。
Front Immunol. 2024 Nov 13;15:1431957. doi: 10.3389/fimmu.2024.1431957. eCollection 2024.
6
Neoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma: A multicenter, phase 2 study.新辅助卡度尼利单抗联合FLOT化疗治疗局部晚期胃/胃食管交界腺癌：一项多中心2期研究。
Med. 2025 Mar 14;6(3):100531. doi: 10.1016/j.medj.2024.10.008. Epub 2024 Nov 12.
7
Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy.病例报告：HER-2扩增阳性的局部晚期胃食管交界癌患者，在新辅助治疗中，在化疗加曲妥珠单抗的基础上加用帕博利珠单抗后实现了病理完全缓解。
Front Immunol. 2025 Feb 12;16:1555074. doi: 10.3389/fimmu.2025.1555074. eCollection 2025.
8
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.一项新辅助多西他赛、奥沙利铂和 S-1（DOS）化疗，随后手术和辅助 S-1 化疗治疗潜在可切除胃或胃食管结合部腺癌的 II 期研究。
Cancer Chemother Pharmacol. 2013 Oct;72(4):815-23. doi: 10.1007/s00280-013-2257-z. Epub 2013 Aug 7.
9
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study.术前化疗后复发风险高（ypN+和/或R1）的胃及食管胃交界癌切除术后患者的辅助免疫治疗：欧洲癌症研究与治疗组织（EORTC）1707 VESTIGE研究
Ann Oncol. 2025 Feb;36(2):197-207. doi: 10.1016/j.annonc.2024.10.829. Epub 2024 Nov 13.
10
The short-term efficacy and safety of neoadjuvant Sintilimab combined with chemotherapy for resectable gastroesophageal junction adenocarcinoma.新辅助信迪利单抗联合化疗治疗可切除胃食管交界腺癌的短期疗效和安全性
Langenbecks Arch Surg. 2024 Dec 12;410(1):5. doi: 10.1007/s00423-024-03576-6.

本文引用的文献

1
The Association Between Breast Cancer Predisposing Genetic Variants and Multifocal, Multicentric Breast Cancer.乳腺癌易感基因变异与多灶性、多中心性乳腺癌的相关性。
Ann Surg Oncol. 2024 Dec;31(13):8891-8899. doi: 10.1245/s10434-024-16243-3. Epub 2024 Sep 27.
2
Prognostic value of tumor regression grade following the administration of neoadjuvant chemotherapy as treatment for gastric/gastroesophageal adenocarcinoma: A meta-analysis of 14 published studies.新辅助化疗治疗胃/胃食管腺癌后肿瘤退缩分级的预后价值：14 项已发表研究的荟萃分析。
Eur J Surg Oncol. 2021 Aug;47(8):1996-2003. doi: 10.1016/j.ejso.2020.12.010. Epub 2020 Dec 19.
3
Gastric cancer.
胃癌。
Lancet. 2020 Aug 29;396(10251):635-648. doi: 10.1016/S0140-6736(20)31288-5.